Continuous Glucose Monitor Insurance Denied? How to Appeal

A continuous glucose monitor (CGM) can be a life-changing device for people managing diabetes. It provides real-time interstitial glucose readings, customizable high/low alerts, trend arrows showing glucose direction and speed of change, and retrospective data that enables more precise therapy adjustments. For patients with Type 1 diabetes (ICD-10 E10.649), insulin-dependent Type 2 diabetes (ICD-10 E11.649), or other forms of diabetes associated with hypoglycemia risk, CGMs are increasingly regarded as a clinical standard of care rather than a supplemental luxury. So when your insurance denies coverage for a CGM, it can feel both frustrating and dangerous. The good news is that CGM denials are frequently overturned on appeal — if you know how to build your case.

Why Insurers Deny CGM Coverage

"Not medically necessary" based on outdated insulin-therapy-only criteria. Insurers historically limited CGM coverage to patients on intensive insulin therapy — multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII/insulin pump). The 2023 ADA Standards of Medical Care in Diabetes now recommend CGM for all people with Type 1 diabetes regardless of insulin regimen, and for people with Type 2 diabetes on insulin who experience hypoglycemia or have suboptimal glycemic control. Plans that have not updated their medical policies to reflect ADA 2023 recommendations are applying obsolete criteria.

Diagnosis-based denials excluding Type 2 or other diabetes types. Some policies limit CGM to Type 1 diabetes only. This conflicts with the ADA's 2023 position and with Medicare's 2023 expanded CGM coverage (CMS Decision Memo CAG-00292R2), which extended coverage to insulin-treated Type 2 patients and, in 2024, to non-insulin-treated beneficiaries meeting clinical criteria.

Denial of upgrade or replacement CGM. Insurers sometimes approve a CGM initially but deny a replacement sensor, transmitter, or upgrade to a newer generation device. CGM sensors and transmitters have defined replacement schedules set by manufacturers and recognized in clinical practice — denial of replacements within those schedules is inconsistent with coverage of the underlying device.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization denial without peer-to-peer offer. Many states have enacted prior authorization reform laws requiring that medical necessity denials offer peer-to-peer review before the denial is finalized. If your insurer issued a CGM denial without offering your endocrinologist a peer-to-peer, you may have grounds to challenge the denial on procedural grounds in addition to medical necessity.

Step therapy requirements. Insurers sometimes require documented failure of fingerstick blood glucose monitoring (FBGM) before approving a CGM — despite clinical evidence that CGM provides information (trend data, nocturnal hypoglycemia detection) that FBGM cannot replicate, and despite ADA 2023 language recommending CGM as a first-line monitoring technology for appropriate patients.

How to Appeal a CGM Denial

Step 1: Obtain and Analyze the Denial Letter

Review the denial for the specific policy provision and clinical criterion cited. Determine whether the denial is based on medical necessity criteria, a formulary or DME coverage rule, or a diagnosis restriction. The appeal strategy differs depending on the denial basis, so precision matters before drafting your response.

Step 2: Obtain a Detailed Letter of Medical Necessity from Your Endocrinologist

Your endocrinologist or diabetes care team should write a letter documenting: your diabetes type and ICD-10 code, current insulin regimen and frequency of dose adjustments, recent HbA1c values, documented episodes of hypoglycemia unawareness or hypoglycemic events, and specific clinical reasons why CGM is necessary to safely manage your diabetes. The letter should cite ADA 2023 Standards of Medical Care, Section 7 (Diabetes Technology), as clinical authority.

Step 3: Cite ADA Guidelines and Medicare Policy as Benchmarks

Reference the 2023 ADA Standards of Medical Care in Diabetes, specifically Section 7 on diabetes technology and CGM recommendations. If you are not on Medicare, note that Medicare's coverage policy (CMS CAG-00292R2) is a strong indicator of clinical consensus and has been recognized by commercial plans as a benchmark for medical necessity. Many commercial plans follow Medicare LCD (Local Coverage Determination) standards as a baseline.

Step 4: Request Peer-to-Peer Review

Your endocrinologist should request a direct conversation with the insurer's medical reviewer. This is often the single most effective step for reversing CGM denials, particularly when the treating physician can explain the specific hypoglycemia risk profile, current HbA1c trajectory, and how CGM trend data enables safer insulin titration than fingerstick monitoring.

Step 5: File a Formal Internal Appeal

Submit a written appeal with the medical necessity letter, ADA 2023 guideline excerpts, recent lab results (HbA1c, hypoglycemia event log), and any peer-reviewed literature on CGM clinical outcomes. If your plan is state-regulated, check whether your state has enacted diabetes technology coverage laws — multiple states have enacted CGM coverage mandates that override insurer criteria.

Step 6: Request External Independent Review

If the internal appeal is denied, request an external independent review through your state insurance commissioner. For endocrinology-related technology denials, external reviewers with diabetes management expertise frequently side with treating physicians following ADA guidelines. External review is binding on the insurer if the reviewer finds in your favor.

What to Include in Your CGM Appeal

• Endocrinologist's letter of medical necessity citing ADA 2023 Section 7 criteria specific to your diabetes type and clinical situation
• Recent HbA1c values (last 2–4 results) and a log of documented hypoglycemic events, including any episodes of hypoglycemia unawareness
• Documentation of your current insulin regimen — type, frequency, basal-bolus rationale — demonstrating the clinical complexity that requires CGM
• Manufacturer clinical validation data for the specific CGM device prescribed (e.g., Dexcom G7 or Abbott Libre 3 clinical studies demonstrating hypoglycemia detection and HbA1c improvement)
• Any state diabetes technology coverage law applicable to your plan type, obtained from your state insurance department

Fight Back With ClaimBack

CGM denials are often based on outdated medical policies that have not been updated to reflect 2023 ADA Standards — and independent reviewers who apply current clinical guidelines reverse these denials at high rates. A structured appeal that cites ADA 2023, documents your specific hypoglycemia risk, and requests peer-to-peer review gives you the strongest possible chance of reversal. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal